BioCardia Company Profile (OTCMKTS:CDOM)

About BioCardia (OTCMKTS:CDOM)

BioCardia logoBioCardia, Inc., formerly Tiger X Medical, Inc., is a clinical-stage regenerative medicine company. The Company is engaged in developing therapeutics for cardiovascular diseases. The Company's lead therapeutic candidate is the CardiAMP Cell Therapy System (CardiAMP). It focuses on the Phase III trial for CardiAMP in ischemic systolic heart failure. The Company also offers CardiALLO Cell Therapy System (CardiALLO), an allogeneic off the shelf mesenchymal stem cell product candidate from other donors. It focuses on the Phase II trial for CardiALLO for the treatment of ischemic systolic heart failure. The Company focuses on various fields of autologous and allogeneic cell-based therapies to manage the lives of patients with cardiovascular conditions. CardiAMP is a therapeutic treatment that includes a companion diagnostic. It consists of a cell potency screening test, a point of care cell processing platform and a biotherapeutic delivery system.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: N/A
  • Sub-Industry: N/A
  • Symbol: OTCMKTS:CDOM
  • CUSIP: N/A
  • Web:
Average Prices:
  • 52 Week Range: $0.05 - $0.18
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0
  • Net Margins: -2,629.46%
  • Return on Equity: -68.61%
  • Return on Assets: -62.94%
  • Current Ratio: 59.03%
  • Average Volume: 297,586 shs.
  • Beta: 0.68

Frequently Asked Questions for BioCardia (OTCMKTS:CDOM)

What is BioCardia's stock symbol?

BioCardia trades on the OTCMKTS under the ticker symbol "CDOM."

Who are some of BioCardia's key competitors?

Who are BioCardia's key executives?

BioCardia's management team includes the folowing people:

  • Simon H. Stertzer M.D., Chairman of the Board
  • Peter Altman Ph.D., President, Chief Executive Officer, Principal Executive Officer, Director
  • David McClung, Principal Financial and Accounting Officer, Vice President - Finance
  • Phil Pesta, Vice President - Operations
  • Fernando L. Fernandez, Director
  • Richard Krasno Ph.D., Director
  • Jay M. Moyes, Director
  • Richard C. Pfenniger Jr., Director
  • Thomas Quertermous M.D., Director

How do I buy BioCardia stock?

Shares of BioCardia can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is BioCardia's stock price today?

One share of BioCardia stock can currently be purchased for approximately $0.12.

MarketBeat Community Rating for BioCardia (OTCMKTS CDOM)
Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  20 (Vote Outperform)
Underperform Votes:  33 (Vote Underperform)
Total Votes:  53
MarketBeat's community ratings are surveys of what our community members think about BioCardia and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for BioCardia (OTCMKTS:CDOM) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for BioCardia (OTCMKTS:CDOM)
No equities research coverage for this company has been tracked by


Earnings History for BioCardia (OTCMKTS:CDOM)
No earnings announcements for this company have been tracked by


Earnings Estimates for BioCardia (OTCMKTS:CDOM)

No earnings estimates for this company have been tracked by


Dividend History for BioCardia (OTCMKTS:CDOM)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for BioCardia (OTCMKTS:CDOM)
Insider Ownership Percentage: 53.30%
Institutional Ownership Percentage: 0.22%
Insider Trades by Quarter for BioCardia (OTCMKTS:CDOM)
Insider Trades by Quarter for BioCardia (OTCMKTS:CDOM)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/10/2016Andrew A. BrooksCEOSell63,560,031$0.10$6,356,003.10View SEC Filing  
5/10/2016Jonathan BrooksDirectorSell31,954,292$0.10$3,195,429.20View SEC Filing  
5/10/2016Phillip Md Et Al FrostMajor ShareholderBuy114,937,148$0.10$11,493,714.80View SEC Filing  
12/10/2015Phillip Md Et Al FrostMajor ShareholderBuy100,000$0.08$8,000.00View SEC Filing  
12/9/2015Phillip Md Et Al FrostMajor ShareholderBuy18,579$0.07$1,300.53View SEC Filing  
12/7/2015Phillip Md Et Al FrostMajor ShareholderBuy500,000$0.07$35,000.00View SEC Filing  
7/17/2015Phillip Md Et Al FrostMajor ShareholderBuy56,100$0.09$5,049.00View SEC Filing  
8/20/2014Phillip Md Et Al FrostMajor ShareholderBuy100,000$0.10$10,000.00View SEC Filing  
8/11/2014Phillip Md Et Al FrostMajor ShareholderBuy50,000$0.11$5,500.00View SEC Filing  
8/1/2014Phillip Md Et Al FrostMajor ShareholderBuy100,000$0.11$11,000.00View SEC Filing  
7/23/2014Phillip Md Et Al FrostMajor ShareholderBuy260,000$0.11$28,600.00View SEC Filing  
5/23/2014Phillip Md Et Al FrostMajor ShareholderBuy100,000$0.09$9,000.00View SEC Filing  
5/19/2014Phillip Md Et Al FrostMajor ShareholderBuy45,700$0.09$4,113.00View SEC Filing  
5/15/2014Phillip Md Et Al FrostMajor ShareholderBuy21,481$0.09$1,933.29View SEC Filing  
5/14/2014Jonathan BrooksDirectorBuy90,000$0.08$7,200.00View SEC Filing  
12/13/2013Thomas H MorganDirectorSell43,000$0.12$5,160.00View SEC Filing  
12/2/2013Thomas H MorganDirectorSell91,350$0.12$10,962.00View SEC Filing  
11/11/2013Thomas H MorganDirectorSell44,000$0.12$5,280.00View SEC Filing  
11/5/2013Thomas H MorganDirectorSell138,462$0.12$16,615.44View SEC Filing  
10/23/2013Jonathan BrooksDirectorSell2,300,000$0.15$345,000.00View SEC Filing  
8/12/2013Andrew A BrooksCEOBuy205,808$0.08$16,464.64View SEC Filing  
1/30/2013Phillip Md Et Al FrostMajor ShareholderBuy194,685$0.07$13,627.95View SEC Filing  
1/14/2013Andrew A BrooksCEOBuy9,000$0.06$540.00View SEC Filing  
1/11/2013Andrew A BrooksCEOBuy760,000$0.06$45,600.00View SEC Filing  
12/31/2012Andrew A BrooksCEOBuy729,205$0.06$43,752.30View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for BioCardia (OTCMKTS:CDOM)
Latest Headlines for BioCardia (OTCMKTS:CDOM)



BioCardia (CDOM) Chart for Tuesday, September, 19, 2017

This page was last updated on 9/19/2017 by Staff